Table 3.
Bleeding risk across eGFR classes according to the diverse eGFR estimating formulas
| eGFR < 30 | eGFR 30–50 | eGFR > 50 | p value | ||||
|---|---|---|---|---|---|---|---|
| Bleeding | Not bleeding | Bleeding | Not bleeding | Bleeding | Not bleeding | ||
| CKD-EPIComb | 23 (11.6) | 176 (88.4) | 42 (13.5) | 270 (86.5) | 38 (12.3) | 271 (87.7) | 0.57 |
| CKD-EPICr | 13 (9.6) | 122 (90.4) | 29 (11.3) | 226 (88.7) | 61 (13.5) | 390 (86.5) | 0.17 |
| MDRD | 10 (9.7) | 93 (90.3) | 28 (10.7) | 233 (89.3) | 65 (13.7) | 410 (86.3) | 0.21 |
| BIS1 | 11 (8.7) | 116 (91.3) | 49 (12.6) | 341 (87.4) | 43 (13.7) | 271 (86.3) | 0.19 |
| BIS2 | 19 (9.6) | 179 (90.4) | 54 (13.6) | 342 (86.4) | 30 (12.3) | 214 (87.7) | 0.41 |
eGFR estimated glomerular filtration rate, CKD-EPICr Chronic Kidney Disease-Epidemiology Collaboration creatinine-based, CKD-EPIComb Chronic Kidney Disease-Epidemiology Collaboration creatinine–cystatin-C based, BIS1 Berlin Initiative Study creatinine, BIS2 Berlin Initiative Study creatinine–cystatin-C, MDRD modification of diet in renal disease